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Abstract
Background: Temporomandibular disorder (TMD) is a multifactorial syndrome related to a critical period of human
life. TMD has been associated with psychological dysfunctions, oxidative state and sexual dimorphism with
coincidental occurrence along the pubertal development. In this work we study the association between TMD and
genetic polymorphisms of folate metabolism, neurotransmission, oxidative and hormonal metabolism. Folate
metabolism, which depends on genes variations and diet, is directly involved in genetic and epigenetic variations
that can influence the changes of last growing period of development in human and the appearance of the TMD.
Methods: A case-control study was designed to evaluate the impact of genetic polymorphisms above described
on TMD. A total of 229 individuals (69% women) were included at the study; 86 were patients with TMD and
143 were healthy control subjects. Subjects underwent to a clinical examination following the guidelines by the
Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD). Genotyping of 20 Single Nucleotide
Polymorphisms (SNPs), divided in two groups, was performed by multiplex minisequencing preceded by
multiplex PCR. Other seven genetic polymorphisms different from SNPs (deletions, insertions, tandem repeat,
null genotype) were achieved by a multiplex-PCR. A chi-square test was performed to determine the differences
in genotype and allelic frequencies between TMD patients and healthy subjects. To estimate TMD risk, in those
polymorphisms that shown significant differences, odds ratio (OR) with a 95% of confidence interval were
calculated.
Results: Six of the polymorphisms showed statistical associations with TMD. Four of them are related to enzymes
of folates metabolism: Allele G of Serine Hydoxymethyltransferase 1 (SHMT1) rs1979277 (OR = 3.99; 95%CI 1.72,
9.25; p = 0.002), allele G of SHMT1 rs638416 (OR = 2.80; 95%CI 1.51, 5.21; p = 0.013), allele T of
Methylentetrahydrofolate Dehydrogenase (MTHFD) rs2236225 (OR = 3.09; 95%CI 1.27, 7.50; p = 0.016) and allele A
of Methionine Synthase Reductase (MTRR) rs1801394 (OR = 2.35; 95CI 1.10, 5.00; p = 0.037). An inflammatory
oxidative stress enzyme, Gluthatione S-Tranferase Mu-1(GSTM1), null allele (OR = 2.21; 95%CI 1.24, 4.36; p = 0.030)
and a neurotransmission receptor, Dopamine Receptor D4 (DRD4), long allele of 48 bp-repeat (OR = 3.62; 95%CI
0.76, 17.26; p = 0.161).
Conclusions: Some genetic polymorphisms related to folates metabolism, inflammatory oxidative stress, and
neurotransmission responses to pain, has been significantly associated to TMD syndrome
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Temporomandibular joint disorder (TMD) is character-
ized by a set of symptoms related to the muscles and
joints that reside between the mandibular condyle and
the temporal bone. The most common symptoms are
joint sounds, pain, and limited joint movement [1].
According to the NIDCR [2] (National Institute of
Dental and Craniofacial Research), 5-12% of the popula-
tion suffers or has suffered at some time from problems
related to temporomandibular joint disorder (TMD) [3].
It is considered the most common cause of chronic pain
in the orofacial region.
There are multiple factors that could cause or contri-
bute to TMD disorder, including trauma, several types
of arthritis, dental problems, autoimmune diseases, psy-
chological and hormonal factors [4] and also commonly
associated with other related symptoms in the head and
neck [5].
Due to its etiological and symptomatic variety, it is
assumed that a combination of factors related to envir-
onmental and/or nutritional stress could be an underly-
i n gc a u s eo fT M D[ 6 - 9 ] .A sf o rg e n e t i cf a c t o r s ,s t u d i e s
of twins and familial segregation suggest that TMD is
not a hereditary disease [10,11]. Nevertheless, indivi-
duals are not equally susceptible to TMD, and different
genetic variants can increase the predisposition to a par-
ticular development of the disorder [12-22].
TMD is a problem that affects women two times more
than men and its causes are not completely known. Cer-
tain hormones can increase inherent genetic vulnerabil-
ity to TMD, which explains the larger predisposition of
women of reproductive age [4,23]. The relationship
between oestrogens and TMD has been studied pre-
viously [24,25]; specifically, the polymorphisms of the
receptor gene ER-a, Pvu II (rs2234693) and Xba I
(rs9340799), seem to be related to several forms of
osteoarthritis, including TMD [17,19].
Folate metabolism can influences the final form of any
growing tissue due not only to its participation in nucleic
acid synthesis, but also to its known function in regulating
DNA and protein methylation. Folate deficiency can cause
central nervous system irritability, depression, weight loss,
and anaemia. Nutritional deficiencies and, more specifi-
cally, abnormally low levels of vitamins B1, B6, B12, and/
or folic acid are considered factors that perpetuate pain
and myofascial dysfunction, and these deficiencies are fre-
quent in cases of TMD mechanical stress [6].
Other mechanisms that have been related to TMD are
factors related to psychopathological and pain percep-
tion, which can also be influenced by genetic variability.
It has been described that the variants of a polymorphic
region linked to gene SLC6A4 of the serotonin transpor-
ter (5-HTT gene-linked polymorphic region, 5-HTTLPR)
[22] could be related to pain perception and temporo-
mandibular disorder [18]. The 44 bp insertion/deletion
polymorphism of the SLC6A4 gene has been extensively
studied and frequently associated with the dopamine
receptor gene DRD4; DRD4 variants have been asso-
ciated with several clinical cases related to behavior, psy-
chopathologies, and pain [17,26,27].
The following objective was to study the implication
of 27 polymorphisms located on 17 genes and their rela-
tion with TMD. It has been designed under the hypoth-
esis of that TMD is a multifactorial syndrome related to
a critical period of human life that have a genetic and
epigenetic basis both associated to folate metabolism,
oxidative stress, hormones and neurotransmission.
Methods
Study design
A case-control study was designed to evaluate the
impact of gene polymorphisms above described on
TMD. A total of 229 individuals (69% women) were
included at the study; 86 were TMD patients and 143
were healthy control subjects. The sample size was cal-
culated using the prevalence of TMD and allele and
genotypes frequencies of the polymorphism selected
based on their known frequency in our population.
Patient recruitment
Thirty five patients diagnosed with TMD who were
admitted consecutively to private dental surgeries (’Clín-
ica Rincon’ and ‘Clínica Dental Aneiros’ in Malaga,
Spain), during a period of 8 months were included in
this study. In addition, 556 volunteer students from
Malaga University (57% female and 43% male) were
invited to participate in the study. They answered a
questionnaire for TMD (Table 1) [28]. Ninety eight indi-
viduals responded affirmatively to four o more question
of the questionnaire. So, they were invited to be clini-
cally evaluated following the guidelines from The
Research Diagnostic Criteria for Temporomandibular
Disorders (RDC/TMD) [29] by a dentist who had
experience in TMD evaluation. Fourteen subjects were
excluded because they could not come to the physical
examination and 33 had not clinical signs of TMD. Case
group was 86 patients (35 previously diagnosed and 51
diagnosed volunteers), 64 women (74%), mean age 19.4
± 2.9, and 22 men (26%) mean age 23.6 ± 4.1. Exclusion
criteria for TMD patients were clinical history of trau-
matic injuries on head and neck, cranial anomalies of
known or unknown etiology, inflammatory chronical
disease component, mental retardation, drug depen-
dence, and somatic or neurological illnesses.
The control group was built from the volunteers who did
not answer affirmatively to any question. All participants
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age matched to the TMD group. In short, control group
consisted in 143 subjects, 94 women (66%), mean age 19,6
±3 . 3 ,a n d4 9m e n( 3 4 % ) ,m e a na g e2 2 , 3±4 . 1 .
All the participants signed an informed consent form,
and their personal data were recorded by interviewers.
The study protocol was approved by Ethics Committee
of Malaga University and conformed to the Helsinki
Declaration.
Samples and DNA isolation method
After obtaining informed consent, oral mucosa samples
were collected from the 229 subjects. DNA isolation was
performed using the salting out method, as described by
Martinez et al. [30], applied to the oral mucosa.
Genotyping
Three platforms were designed to perform the genotyp-
ing. Two of them for 20 Single Nucleotide Polymorph-
isms (SNP1, SNP2) and the third one for other
polymorphisms of 7 gene variants (deletions, insertions,
tandem repeat, null genotype). Primers were designed
using the primer analysis software Oligo, version 4.0 and
synthesized commercially. The primers sequences are
shown in table 2. To verify the validity and reliability of
the techniques, the quality of each isolated polymorph-
ism was checked in a simplex reaction.
SNPs
Genotyping of SNPs was performed by multiplex minis-
equencing preceded by multiplex PCR [31]. This techni-
que consists of three steps:
1) Amplification of regions flanking the SNPs by mul-
tiplex PCR; PCR reactions were performed in a volume
of 10 μL with 100 ng of genomic DNA, 1×Amplitaq
Gold
® Buffer (Applied Biosystems), MgCl2 1,5 mM,
dNTPs 0,2 mM, 1 unit of Amplitaq Gold
® DNA Poly-
merase (Applied Biosystems) and Primer Mix (primer
concentrations ranged between 0,1-0,6 μM). Amplifica-
tion was achieved in a 2720 Thermal Cycler
®(Applied
Biosystems) and consisted of 94°C for 5 minutes, fol-
lowed by 35 cycles for 30 s at 94°C, 30 s at 58°C; 30 s at
72°C and a final extension for 7 min at 72°C. PCR pro-
ducts were checked in a 2% agarose gel, stained with
SYBR
® Safe DNA gel stain (Invitrogen) which resulted
in 100 to 400 bp sized bands. In order to eliminate the
excess of primers and dNTPs, the PCR products were
digested by an ‘ExoCiAP’ mix consisting of 2 units/
10 μLP C RE. coli exonuclease I (Exo I, Takara
®)a n d
5 units/10 μLPCR alkaline phosphatase (CiAP, Takara
®)
incubated at 37°C for 60 minutes. The enzymes were
afterwards inactivated by heating at 80°C for 20 minutes
2) Multiplex mini-sequencing for each locus of the
SNP multiplexes (SNP1, SNP2), a mini-sequencing pri-
mer with the 3’-end adjacent to the target SNP was
designed (see Table 2) to anneal with the PCR product.
A mini-sequencing reaction extends this primer, produ-
cing different products for each allele. We performed
the reaction in a 11 μLv o l u m ew i t h4μL purified PCR
product and 6 μL of the mini-sequencing primers mix
(2 pM/μL) and 1 μLo fS N a P s h o t
® multiplex kit
(Applied Biosystems). The mini-sequencing conditions
consisted of 40 cycles at 96°C-10 s; 50°C-7 s; 60°C-30 s.
After that, we proceeded to purify the sample using
1u n i to falkaline phosphatase (Takara
®)a t3 7 ° Cf o r
1 hour and then at 80°C for 20 min.
3) Analysis of mini-sequencing products by capillary
electrophoresis: We mixed 4 μlo ft h ep u r i f i e dm i n i -
sequencing products with 10 μlo fH i D i ™ formamide
and 0.2 μl of GeneScan-120 LIZ size standard (Applied
Biosystems) and denatured at 95°C for 5 minutes. The
fluorescently labeled products were resolved by capillary
electrophoresis on an ABI PRISM 3130 Genetic Analy-
zer (Applied Biosystems). The DS02 matrix (Applied
Biosystems) was used at full speed for 17 minutes with
8 seconds of injection. The resulting data were analyzed
with GeneMapper™ 4.0 Software (Applied Biosystems).
Other polymorphisms
To detect other polymorphisms different from SNPs
(deletions, insertions, tandem repeat, null genotype), a
multiplex PCR assay was performed under the following
concentrations (in a volume of 10 μL): 100 ng of geno-
mic DNA, 1× GoTaq
® FlexiBuffer (Promega), MgCl2
1,5 mM, dNTPs 0,2 mM, Primer Mix (primer concentra-
tions ranged between 0,1-0,6 μM), Betaine 50 mM and
1u n i to fG oT a q
® Flexi DNA Polymerase (Promega).
The labeled primers are shown in table 2. Amplification
was achieved in a 2720 Thermal Cycler
® (Applied Biosys-
tems) and consisted of 94°C for 5 minutes, followed by 35
cycles for 30 s at 94°C, 45 s at 58°C; 1 min at 72°C and a
final extension for 7 min at 72°C. We mixed 4 μlo fP C R
Table 1 Questionnaire form for TMD
1. Do you have difficulty or pain, or both, when opening your mouth,
as for instance, when yawning?
2. Does your jaw get stuck, locked, or go out?
3. Do you have difficulty or pain, or both, when chewing, talking, or
using your jaws?
4. Are you aware of noises in the jaw joints?
5. Do you have pain in or about the ears, temples, or cheeks?
6. Does your bite feel uncomfortable or unusual?
7. Do you have frequent headaches?
8. Have you had a recent injury to your head, neck, or jaw?
9. Have you previously been treated for a jaw joint problem? If so,
when?
From J Am Dent Assoc 1990, 120: 253-254.
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Name Reference SNP/F Location A1 A2 Forward Primers Reverse Primers Minisequencing Primers Mult.
SHMT1 rs1979276 SNP 3’-UTR A G CTGGCAGGGGATAAGTACCAG GTCAACAGTTCCCCTTTGGA CCGGAGGACCCCCAC SNP1
rs1979277 SNP EXON A G CTGGCAGGGGATAAGTACCAG GTCAACAGTTCCCCTTTGGA (T)31-GCCAGGCAGAGGGAAGA SNP1
rs643333 SNP 5’-UTR A C TGGACGCACATTTGTCCTAC ATCAGAGAGCGCAGCCAAG (T)24-ACCTGCAGAACTGACCC SNP1
rs638416 SNP 5’-UTR C G TGGACGCACATTTGTCCTAC ATCAGAGAGCGCAGCCAAG (T)91-GCAGGGCCTGTTTCTCC SNP1
rs3783 SNP 3’-UTR C G CTGGCAGGGGATAAGTACCAG GTCAACAGTTCCCCTTTGGA (T)115-GGGGTCCTCCGGCAG SNP1
TYMS rs2853542 SNP 5’-UTR C G GTGCCACACCCGTGGCTCC GCCACAGGCATGGCGCGG (T)84-GGGACGGAGGCAGGC SNP1
rs34489327 F 3’-UTR I D PET-CAAATCTGAGGGAGCTGAGT CAGATAAGTGGCAGTACAGA F
rs34743033 F 5’-UTR 2R 3R VIC-GTGCCACACCCGTGGCTCC GCCACAGGCATGGCGCGG F
TCN rs9606756 SNP EXON A G GGAGAAGGCCCTGGTAACG CTTCCTTGGTCCCAGCCTG (T)64-GGCTGTCCATCTCTGGTA SNP1
rs1801198 SNP EXON C G GGGAAAGAGACCCTGGAGC GCTGGGAAATCATGAGAGC (T)58-CCCAGTTCTGCCCCA SNP2
MTHFR rs1801131 SNP EXON A C CTTTGGGGAGCTGAAGGACTACTAC CACTTTGTGACCATTCCGGTTTG (T)71-AGGAGCTGACCAGTGAAG SNP2
rs1801133 SNP EXON C T GTGGTCTCTTCATCCCTCG GACGGTGCGGTGAGAGTG GAAGGTGTCTGCGGGAG SNP2
CBS rs5742905 SNP EXON C T GGTTCTTGGGTTTCTCATCC CTCCGTCTGGTTCAGCTCC (T)42-GCGCCCTCTGCAGATCA SNP2
cbs844ins68 F INTR/EXON S L 6FAM-GTTGTTAACGGCGGTATTGG GTTGTCTGCTCCGTCTGGTT F
ABCB1 rs1045642 SNP EXON C T GCTGAGAACATTGCCTATGG TAAGGGTGTGATTTGGTTGC (T)34-GGTGTCACAGGAAGAGAT SNP2
ATIC rs2372536 SNP EXON C G CCTAGATAGCTGTAAACCAC GTAATCCCAAAACACAATC (T)18-CCACAGCCTCCTCAACA SNP1
BHMT rs3733890 SNP EXON A G TGTGAACTGCCACTTTGACC ATGGGAATTCTGGGAGATCG ATCAGGTGAGCTTTCAGT SNP1
DHFR DHFR19bpdel F INTRON + - ACGGTCGGGGTGGCCGACTC 6FAM-AAAAGGGGAATCCAGTCGG F
GSTM1 GSTM1del F EXON + - PET-GAACTCCCTGAAAAGCTAAAGC GTTGGGCTCAAATATACGGTGG F
MTHFD1 rs2236225 SNP EXON C T CCCACTTTGAAGCAGGATTG CATCCCAATTCCCCTGATG (T)59-AACAAGCTTGAGTGCGATC SNP1
MTR rs12749581 SNP EXON A G GCATTGACCATTACTACACC TCCAAAGCCTTTTACACTCC AATATGAAGATATTAGACAGG SNP2
MTRR rs1801394 SNP EXON A G TTTCAGTTTCACTGTTACATGC GTAACGGCTCTAACCTTATCG (T)51-ACCACAGCTTGCTCACA SNP1
RFC1 rs1051266 SNP EXON A G TTCCAGGCACAGTGTCACC CCGCGTGAAGTTCTTGTCG (T)40-CCGGTCCTGGCGGC SNP1
ESR1 rs9340799 SNP INTRON A G AGGGTTATGTGGCAATGACG CTGCACCAGAATATGTTACC (T)4-AGACCCTGAGTGTGGTCT SNP2
rs2234693 SNP INTRON C T AGGGTTATGTGGCAATGACG CTGCACCAGAATATGTTACC (T)28-AGTTCCAAATGTCCCAGC SNP2
DRD4 drd4-48bptr F EXON S L NED-GCTGCTGCTCTACTGGGC CCCGGCCGGTGATCTTGG F
SLC6A4 SCL6A45-HTTLPR F 5-HTTLPR S L VIC-GCGTTGCCGCTCTGAAGTC GTGCCACCTAGACGCCAGG F
SNP = Single Nucleotide Polimorphism; F = Fragment or Repeat; A1 = Allele 1; Allele2; MULT = Multiplex Reaction;SHMT1 = Serine Hydroxymethyltransferase1; TYMS = Thymidylate Synthetase; TCN = Transcobalamin
II; MTHFR = 5,10-Methylenetetrahydrofolate Reductase; CBS = Cystathionine Beta-Synthase; ABCB1 = ATP-Binding Cassette B1; ATIC = 5-Aminoimidazole-4-Carboxamide Ribonucleotide Formyltransferase/IMP
Cyclohydrolase; BHMT = Betaine-Homocysteine Methyltransferase; DHFR = Dihydrofolate Reductase; MTHFD1 = Methylenetetrahydrofolate Dehydrogenase 1; MTR = 5-Methyltetrahydrofolate-Homocysteine S-
Methyltransferase; MTRR = Methionine Synthase Reductase; RFC1 = Reduced Folate Carrier 1; ESR1 = Estrogen Receptor 1; DRD4 = Dopamine Receptor D4; SLC6A4 = Solute Carrier Family 6.
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9products with 10 μlo fH i D i ™ formamide and 0.2 μL of
GeneScan-600 LIZ size standard (Applied Biosystems)
and denatured at 95°C for 5 minutes. The fluorescently
labeled products were resolved by capillary electrophor-
esis on an ABI PRISM 3130 Genetic Analyzer (Applied
Biosystems). The DS33 matrix (Applied Biosystems) was
used at full speed for 45 minutes with 5 seconds of injec-
tion. The sizes of the alleles were analyzed with Gene-
Mapper Ver. 4.0 (Applied Biosystems) software.
Statistics
All analyses were performed using Statistical Package for
Social Sciences statistical software (SPSS v. 16.0 for
Macintosh; SPSS Inc., Chicago, IL). To determine the dif-
ferences in genotype and allelic frequency of each studied
polymorphism between TMD patients and healthy sub-
jects, a chi-square test was used. Any p value < 0.05 was
considered as a statistical difference. In those polymorph-
isms that shown significant difference in genotype, the
risk between subjects with TMD and healthy controls
was evaluated by Cochran’s-Haenzel odds ratios with a
95% confidence interval using sex as confounding factor.
Results
Genotyping was performed for the 229 individuals. The
results are summarized in Table 3. Not all of the samples
were valid for all genotypes, because of that, the number of
individuals can vary from one polymorphism to another.
Serine Hidroximetil Transferase 1 gene (SHMT1)
This enzyme catalyzes the reversible conversion of
serine to glycine, transferring methyl groups to tetrahy-
drofolate (THF), which is transformed into 5,10-methy-
lenetetrahydrofolate (5,10-CH2-THF). During cellular
proliferation, this is the predominant pathway for pyri-
midine synthesis (see Figure 1).
From the four polymorphisms studied on the cytoplas-
mic SHMT1 in TMD patients, a significant increase was
observed of the G allele of the polymorphism rs1979277
(Leu435Phe) when compared with controls (OR = 3.99;
95% CI 1.72, 9.25; p = 0,002). Regarding the polymorph-
ism SHMT1 rs638416 of the promoter region (5’-UTR),
a very significant increase was observed of the C allele
and the CC genotype in TMD patients (OR = 2.80; 95%
CI 1.51, 5.21; p = 0,013). Both polymorphisms are not
linked [32], so their frequencies can be measured inde-
pendently as a risk factor for TMD.
Methylenetetrahydrofolate dehydrogenase 1 gene
(MTHFD1)
The MTHFD1 gene encodes a protein that has three dis-
tinct enzyme activities: 5,10-methylenetetrahydrofolate
dehydrogenase, 5,10-methylenetetrahydrofolate cyclo-
hydrolase, and 10-formyltetrahydrofolate-synthetase.
Each of these activities catalyzes one of three intercon-
version reactions of one-carbon derivatives of THF,
which are substrates for the synthesis of methionine, thy-
midylate and purines. The trifunctional enzymatic activ-
ity is conferred by two larger domains: a terminal amino
portion with dehydrogenase and cyclohydrolase activities
and a larger domain with synthetase activity.
The transition from G to A (rs2236225) in the
MTHFD1 gene that results in an alteration of ARG-
653-GLN is clinically associated with susceptibility to
neural tube defects (NTDs) sensitive to folates [33]. In
our study, we found statistical differences in the alleles
and genotypes frequencies between TMD patients and
healthy controls. The T allele was more frequent in
TMD patients (OR = 3.09; 95% CI 1.27, 7.50; p =
0,016).
Glutathione S-transferase mu 1 (GSTM1) gene
This gene encodes mu-class glutathione S-transferase.
Its function is the detoxification of electrophilic com-
pounds, including carcinogens, drugs, toxins, and pro-
ducts of oxidative stress, by the conjugation with
glutathione.
The GSTM1-null polymorphism is a deletion of the
GSTM1 gene. The null variant of this gene has been
associated with an increase of cancer and male infertility
[34,35] possibly due to greater susceptibility to environ-
mental toxins and carcinogens as well as an alteration in
the toxicity and efficiency of certain substances.
Our study found a statistical increase (OR = 2.21; 95%
CI 1.24, 4.36; p = 0.030) of the null variant in TMD
patients compared to the control group.
Methionine Synthase Reductase (MTRR) gene
MTRR is responsible for the regeneration of Methionine
Synthase (MTR) by reductive methylation using SAM as
a methyl donor.
The substitution of A by G (rs1801394) in the encod-
ing region is translated in Ile22Met. The G allele pro-
duces an enzyme with less affinity for the substrate [36].
A statistical increase of the A allele (OR = 2.35; 95% CI
1.10, 5.00; p = 0.037) was observed in the TMD group.
D4 receptor of Dopamine (DRD4) gene
DRD4-48bptr is the 48-bp VNTR in exon 3 of the
DRD4, which encodes the third intracellular receptor
loop and presents between 2 to 11 repeats. According to
the number of repetitions, we can characterize the poly-
morphism as the short allele S-DRD4 (2 to 5 repeti-
tions) and the long allele L-DRD4 (6 or more repeats)
[37]. It was observed statistical differences on genotype
frequencies in both groups (p = 0,039), but no statistical
increase (OR = 3.12; 95% IC 0.76, 17.26, p = 0.181) of
the S-DRD4 allele was found in patient group. The LL
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GENE REFERENCE ALELLE PATIENTS CONTROLS ODDS RATIOS
G1 G2 G3 A1/A2 G1 G2 G3 A1/A2 Χ
2genotype Allele OD 95%CI p
SHMT1 rs1979276 A/G 7 (0,10) 36 (0,49) 30 (0,41) 0,34/0,66 24 (0,20) 54 (0,45) 41 (0,34) 0,43/0,57
rs1979277 A/G 8 (0,11) 31 (0,44) 32 (0,45) 0,33/0,67 35 (0,34) 28 (0,27) 41 (0,39) 0,47/0,53 0,002 G 3,99 1,72-9,25 0,002
rs643333 A/C 3 (0,04) 32 (0,43) 39 (0,53) 0,26/0,74 10 (0,08) 47 (0,39) 64 (0,53) 0,28/0,72 ns -
rs638416 C/G 19 (0,24) 39 (0,50) 20 (0,26) 0,49/0,51 12 (0,10) 50 (0,41) 60 (0,49) 0,30/0,70 0,001 C 2,80 1,51-5,21 0,013
rs3783 C/G 1 (0,01) 27 (0,36) 46 (0,62) 0,20/0,80 2 (0,02) 33 (0,28) 85 (0,71) 0,15/0,85 ns -
TYMS rs2853542 C/G 55 (0,73) 20 (0,27) 0 (0,00) 0,87/0,13 96 (0,76) 30 (0,24) 0 (0,00) 0,88/0,12 ns -
rs34489327 DI 9 (0,13) 25 (0,35) 38 (0,53) 0,30/0,70 7 (0,08) 32 (0,34) 54 (0,58) 0,25/0,75 ns -
rs34743033 2R3R 12 (0,17) 36 (0,50) 24 (0,33) 0,42/0,58 10 (0,12) 55 (0,64) 21 (0,24) 0,44/0,56 ns -
TCN rs9606756 A/G 57 (0,75) 16 (0,21) 3 (0,04) 0,86/0,14 85 (0,73) 30 (0,26) 1 (0,01) 0,86/0,14 ns -
rs1801198 C/G 30 (0,38) 38 (0,49) 10 (0,13) 0,63/0,37 56 (0,46) 61 (0,50) 6 (0,05) 0,70/0,30 ns -
MTHFR rs1801131 A/C 44 (0,57) 25 (0,32) 8 (0,10) 0,73/0,27 64 (0,53) 47 (0,39) 10 (0,08) 0,72/0,28 ns -
rs1801133 C/T 27 (0,35) 37 (0,48) 13 (0,17) 0,59/0,41 43 (0,34) 62 (0,49) 22 (0,17) 0,58/0,42 ns -
CBS rs5742905 C/T 0 (0,00) 12 (0,18) 54 (0,82) 0,09/0,91 2 (0,02) 27 (0,25) 81 (0,74) 0,14/0,86 ns -
cbs844ins68 SL 59 (0,84) 11 (0,16) 0 (0,00) 0,92/0,08 68 (0,81) 14 (0,17) 2 (0,02) 0,89/0,11 ns -
ABCB1 rs1045642 C/T 28 (0,36) 38 (0,49) 12 (0,15) 0,60/0,40 30 (0,24) 64 (0,51) 31 (0,25) 0,50/0,50 ns -
ATIC rs2372536 C/G 23 (0,49) 18 (0,38) 6 (0,13) 0,68/0,32 44 (0,43) 42 (0,41) 17 (0,17) 0,63/0,37 ns -
BHMT rs3733890 A/G 11 (0,15) 29 (0,40) 32 (0,44) 0,35/0,65 17 (0,14) 54 (0,45) 49 (0,41) 0,37/0,63 ns -
DHFR DHFR19del -+ 22 (0,31) 31 (0,43) 19 (0,26) 0,52/0,48 29 (0,31) 48 (0,52) 16 (0,17) 0,57/0,43 ns -
GSTM1 GSTM1del - 17 (0,23) 56 (0,77) 0,62/0,38 39 (0,40) 58 (0,60) 0,70/0,30 0,015 null 2,21 1,24-4,36 0,030
MTHFD1 rs2236225 C/T 7 (0,09) 47 (0,63) 21 (0,28) 0,41/0,59 28 (0,24) 70 (0,60) 18 (0,16) 0,54/0,46 0,011 T 3,09 1,27-7,50 0,016
MTR rs1805087 A/G 55 (0,71) 20 (0,26) 2 (0,03) 0,84/0,16 80 (0,63) 42 (0,33) 4 (0,03) 0,80/0,20 ns -
MTRR rs1801394 A/G 28 (0,37) 37 (0,49) 11 (0,14) 0,61/0,39 29 (0,25) 54 (0,47) 33 (0,28) 0,48/0,52 0,046 A 2,35 1,10-5,00
RFC1 rs1051266 A/G 15 (0,20) 42 (0,55) 19 (0,25) 0,47/0,53 28 (0,23) 59 (0,49) 33 (0,28) 0,48/0,52 ns -
ESR1 rs9340799 A/G 37 (0,48) 35 (0,45) 5 (0,06) 0,71 55 (0,43) 59 (0,46) 13 (0,10) 0,67/0,33 ns -
rs2234693 C/T 13 (0,17) 44 (0,56) 21 (0,27) 0,45 32 (0,25) 60 (0,48) 34 (0,27) 0,49/0,51 ns -
DRD4 drd448bptr SL 50 (0,96) 2 (0,04) 0 (0,00) 0,98 69 (0,87) 7 (0,09) 3 (0,04) 0,92 0,039 L 3,12 0,76-17,2 0,161
SCL6A4 5-HTTLPR SL 20 (0,43) 16 (0,35) 10 (0,22) 0,61 31 (0,40) 32 (0,41) 15 (0,19) 0,60 ns -
ns = no statistical difference.
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9genotype was not found in any of the individuals with
TMD.
Discussion
Temporomandibular disorder has been associated with
psychological dysfunctions [38], and sexual dimorphism
[24]. Its occurrence also appears to coincide with puberty
[25]. Currently, controversy exists as to the importance
of underlying genetic and environmental nutritional fac-
tors, such as vitamin intake [7]. The folate-methionine
axis takes part in both factors. In this axis, there are sev-
eral polymorphic variants of the enzymes involved that
together with folate dietary intake determines the meta-
bolism of the axis. Furthermore, the transfer of methyl
groups to DNA and proteins is one of the limiting factors
for the correct development of the proliferating tissues.
Therefore the latter is key for the continuous tissue
growth and epigenetic modifications.
This work studied the implication of 27 polymorph-
isms located on 17 genes and their relation with TMD.
It has been designed under the hypothesis of that TMD
is a multifactorial syndrome related to a critical period
of human life that have a genetic and epigenetic basis
[12-22]. The study of genes related to folate cycle is
directly involved in the two ways: the genetic, by gene
polymorphisms, and epigenetic by the nutritional habits
because of the folate intake. Deficit of folate intake is
known as the most prevalent vitamin deficit in human.
The majority of the genes studied were related to folate
metabolism even though there were others related to
oxidative metabolism and hormonal and neurotransmis-
sion receptors. Of the17 genes studied of the folate
cycle, 3 of them (SHMT, MTHFD, MTRR) showed sig-
nificant associations with TMD. Significant changes in
the allele and genotype frequencies between the TMD
patients and controls were found.
SHMT catalyzes a reversible step of THF to 5,10-CH2-
THF, which is a key substrate to obtain 5-methyl-THF
and synthesize thymidylate. On the other hand,
MTHFD1 provides the 5, 10CH2-THF substrate in addi-
tion to having a central role in the cycle due to its triple
functionality. The 5-methyl-THF to methionine step is
catalyzed by MTR in cooperation with TCN and MTRR,
which are essential for the participation of vitamin B12
as a cofactor and the reactivation of MTR, respectively.
In our case, a higher significant frequency of the allele
SHMT-rs1979277G was observed in TMD patients (0.67
vs 0.53). The Allele G has been related to higher levels
of folates and homocysteine [39], this could mean that
the enzyme activity is deviated to the THF and glycine
synthesis versus to the serine and 5,10CH3THF sub-
strate of the MTHFR which provide 5’CH3THF needed
to the methionine synthesis by mean of homocysteine.
The increase of homocysteine, classified as an oxidant,
could favour inflamatory process. However the effect of
this polymorphism on enzyme activity is still contro-
verted [39].
Statistical differences were also observed in allelic fre-
quency of the C allele the SNP rs638416, in the promo-
ter region of the SHMT gene. SHMT not only provides
one-carbon units for thymidylate biosynthesis but also
generates a pool of methylenetetrahydrofolate for SAM
synthesis by means of serine synthesis. In addition, the
SHMT gene has the capacity to sequester 5-methyl-THF
and therefore inhibit the synthesis of methionine and
SAM, which is the methyl donor for DNA and proteins
[39]. Therefore, greater SHMT activity would produce
higher 5-methyl-THF sequestration, which would reduce
SAM synthesis. Cellular deficits of SAM could induce
lesser methylation on the novo synthetized DNA on
inflamatory tissues, which can take to higher gene
expresión levels, generating a positive feedback on
inflammation and pain.
TMD patients and healthy controls had very signifi-
cantly different genotypic frequencies of the SNP
rs2236225 of the MTHFD gene. The triple functionality
of the MTHFD enzyme and the central role it plays in
t h ef o l a t ec y c l em a k ei to n eo ft h ek e yp o i n t sf o rt h e
Figure 1 The Folate and methionine cycles. Abreviations: 10f-
THF: 10-formyltetrahydrofolate; 5,10-CH2-THF: 5,10-
methylenetetrahydrofolate; 5,10-CH-THF: 5,10-
methenyltetrahydrofolate; 5mTHF: 5-methyltetrahydrofolate; AICART:
Aminoimidazolecarboxamide ribotide transformylase; ATIC: 5-
aminoimidazole-4-carboxamide ribonucleotide formyltransferase/imp
cyclohydrolase; BHMT: Betaine-homocysteine methyltransferase; CBS:
Cystathionine beta-synthase; DHF: Dihydrofolate reductase; DNMT: S-
adenosylmethionine-dependent methyltransferases; DNMT, DNA
methyltransferase; FTD: 10-formyltetrahydrofolate dehydrogenase;
FTS: 10-formyltetrahydrofolate synthase; GNMT: glycine N-
methyltransferase; GST: Glutathione S-transferase; MAT: methionine
adenosyltransferase; MTCH: 5,10-methylenetetrahydrofolate
cyclohydrolase; MTD: Methylenetetrahydrofolate dehydrogenase;
MTHFR: 5,10-methylenetetrahydrofolate reductase; MTR: 5-
methyltetrahydrofolate-homocysteine S-methyltransferase; MTRR:
Methionine synthase reductase; NE: nonenzymatic interconversion
of THF; PGT: phosphoribosyl glycinamidetransformylase; SAH: S-
adenosylhomocysteine; SAHH: S-adenosyl homocysteine hydrolase;
SAM: S-adenosylmethionine; SHMT: Serine hydroxymethyltransferase;
TCN2: Transcobalamin II; THF: tetrahydrofolate; TS: thymidylate
synthase; TYMS: Thymidylate synthetase.
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difficult to believe that any genetic alteration that affects
its expression or activity would have consequences for
methyl transfer and consequently on epigenesis.
The results of the present work show that the poly-
morphic variants SHMT-rs1979277, rs638416, and
MTHFD1-rs2236225 found in the folate cycle were signifi-
cantly associated with TMD. They coincided with a global
decrease in the availability of methyl groups via a decrease
of the substrate 5,10-CH2-THF (SHMT and MTHFD1),
while the SNP MTRR-rs1801394 did not follow the same
pattern. The wild allele A, predominant in TMD, which
means greater efficiency in the pathway of homocysteine
to methionine, has the same final effect of the variants of
SHMT and MTHFD, an increase of THF levels.
TMD have been associated to oxidative stress of the
temporomandibular joint [40-44]. Regarding GTSM1,
we found a significant number of individuals with TMD
(OD = 2.21; 95%CI 1.24, 4.35; p = 0.030) with the null
variant of the gene. It has been published that oxidative
stress, which leads to the production of NO and peroxy-
nitrite, is harmful to DNA in response to the excessive
mechanical overload, which in turn promotes synovial
hyperplasia in the temporomandibular joint [40]. This
suggests that a reduced detoxification capacity would
make us more susceptible to TMD.
Previous studies on associations of TMD with alpha
ESR1 polymorphisms have shown different results. One
of them find a predisposition to TMD associated to
ESR1 polymorphism in women [15] others find a rela-
tion between pain [17] or craniofacial morphology [19]
in TMD women with ESR1 polymorphism, however
other recent report does not find this association[12]. In
the present study there were no statistical differences in
their individualized allelic and genotypic frequencies or
in the distinct haplotype combinations. However, a
study on the association between these polymorphisms
and the predisposition to TMD has recently been pub-
lished and deepens the characterization of the diplotypes
using novel mathematic algorithms[15], which we will
take into account in future studies.
In contrast to others authors [18,21], significant varia-
tions were not found in the frequencies of the 5-
HTTLPR (serotonin-transporter-linked promoter region)
polymorphism of the serotonin receptor gene SCL6A4.
However, we found a significant variation in the 48-bp
VNTR polymorphism of the DRD4 gene. This poly-
morphism has been associated with pain processes, such
as fibromyalgia [35] and migraine [36].
Conclusions
In this study we have found new associations of poly-
morphic genes, related to folates, SHMT, MTHFD and
MTR, oxidative stress GSTM1 and neurotransmission
D R D 4 ,w i t hT M D .C o n c l u d i n gt h a tt h ee m e r g e n c eo f
TMD in the tissues involved in joint morphogenesis in
the final phase of maturity may occur due to multiple
factors. Among those factors, we have found genetic
polymorphisms involving folate deficiency, psycho-physi-
cal stress and the oxidative metabolism in cellular prolif-
eration during puberty. The novelty of the results
obtained in this study should be confirmed and
extended in subsequent work with larger populations.
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